TY - JOUR T1 - Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis JF - medRxiv DO - 10.1101/2020.08.21.20179234 SP - 2020.08.21.20179234 AU - Cori Campbell AU - Tingyan Wang AU - Anna McNaughton AU - Eleanor Barnes AU - Philippa C Matthews Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/24/2020.08.21.20179234.abstract N2 - Background Hepatocellular carcinoma (HCC) is one of the leading contributors to cancer mortality worldwide and is the largest cause of death in individuals with chronic hepatitis B virus (HBV) infection. It is not certain how the presence of other metabolic factors and comorbidities influences HCC risk in HBV. Therefore we performed a systematic review and meta-analysis to seek evidence for significant associations.Methods MEDLINE, Embase and Web of Science databases were searched from 1st January 2000 to 24th June 2020 for English studies investigating associations of metabolic factors and comorbidities with HCC risk in individuals with chronic HBV infection. We extracted data for meta-analysis and report pooled effect estimates from a fixed-effects model. Pooled estimates from a random-effects model were also generated if significant heterogeneity was present.Results We identified 40 observational studies reporting on associations of diabetes mellitus, hypertension, dyslipiaemia and obesity with HCC risk. Meta-analysis was possible for only diabetes mellitus due to the limited number of studies. Diabetes mellitus was associated with > 25% increase in hazards of HCC (fixed effects Hazards Ratio [HR] 1.26, 95% CI 1.20–1.32, random effects HR 1.36, 95% CI 1.23–1.49). This association was attenuated towards the null in sensitivity analysis restricted to studies adjusted for metformin use.Conclusions In adults with chronic HBV infection, diabetes mellitus is a significant risk factor for HCC, but further investigation of how antidiabetic drug use and glycaemic control influence this association is needed. Enhanced screening of individuals with HBV and diabetes may be warranted.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCC acknowledges doctoral funding from GlaxoSmithKline.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/A, meta-analysisAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A, meta-analysis ER -